联盟全球合作伙伴 (OTCMKTS: CRLBF) 下调了 Cresco Labs Inc. 2022 年第四季度每股收益预期

富途牛牛综合

2023.02.2414:23

关注

Cresco Labs Inc. (OTCMKTS:CRLBF – Get Rating) – Equities researchers at Alliance Global Partners dropped their Q4 2022 earnings per share (EPS) estimates for Cresco Labs in a research report issued on Wednesday, February 22nd. Alliance Global Partners analyst A. Grey now expects that the company will post earnings of $0.02 per share for the quarter, down from their previous forecast of $0.03. The consensus estimate for Cresco Labs' current full-year earnings is ($0.11) per share. Alliance Global Partners also issued estimates for Cresco Labs' Q1 2023 earnings at $0.03 EPS, Q2 2023 earnings at $0.04 EPS, Q3 2023 earnings at $0.05 EPS, Q4 2023 earnings at $0.05 EPS, FY2023 earnings at $0.17 EPS and FY2024 earnings at $0.23 EPS.

Get

Cresco Labs

alerts:

Other equities research analysts have also issued research reports about the company. BTIG Research reaffirmed a "buy" rating on shares of Cresco Labs in a research note on Friday, October 28th. Stifel Nicolaus lowered their price target on shares of Cresco Labs from C$4.75 to C$2.75 in a research note on Wednesday, February 8th. Wedbush started coverage on Cresco Labs in a research note on Thursday, December 1st. They issued an "outperform" rating and a $4.50 target price for the company. Cowen cut shares of Cresco Labs from an "outperform" rating to a "market perform" rating in a research report on Tuesday, December 20th. Finally, Cantor Fitzgerald reduced their price target on Cresco Labs from $15.00 to $14.25 and set an "overweight" rating on the stock in a report on Friday, December 30th. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $6.86.

Cresco Labs Trading Down 1.9 %

Shares of CRLBF opened at $1.78 on Thursday. The firm's 50 day simple moving average is $1.89 and its 200 day simple moving average is $2.84. The company has a market capitalization of $480.65 million and a P/E ratio of -7.12. Cresco Labs has a 1-year low of $1.65 and a 1-year high of $7.01. The company has a debt-to-equity ratio of 0.81, a current ratio of 1.31 and a quick ratio of 0.75.

Cresco Labs Company Profile

(Get Rating)

Cresco Labs Inc, together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; vape carts, vape pens, flower, popcorn, shake, pre-rolls, shorties, and concentrates under the High Supply brand; vapes and gummies under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, and sublingual oils under the Remedi brand, as well as cannabis products under the Reserve brand.